Predictors of CD4 count changes over time among children who initiated highly active antiretroviral therapy in Ethiopia
Open Access
- 22 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Tropical Medicine and Health
- Vol. 48 (1), 1-8
- https://doi.org/10.1186/s41182-020-00224-9
Abstract
Introduction Human immunodeficiency virus (HIV) infection results in a gradual depletion of immune function, particularly CD4 cells. The CD4 assessment plays a significant role in assessing treatment responses and clinical decision-making for patients on combination antiretroviral therapy (ART) in resource-limited settings. However, new data on CD4 count changes are scarce; the volatility of CD4 counts after initiation of ART over time remains largely uncharacterized. This study aimed to identify the predictors of CD4 changes over time among HIV-infected children who began ART in Amhara, Ethiopia. Methods A retrospective follow-up study was performed. A total of 983 HIV-infected children who initiated ART in government hospitals in the Amhara region between 2010 and 2016 were included using a simple random sampling technique. Data were extracted using a structured checklist. An exploratory data analysis was carried out to explain individual and average profile plots. The linear mixed model was used to identify the CD4 change count predictors over time. Variables with p value < 0.05 were considered statistically significant in a multivariable linear mixed regression analysis. Results The mean CD4 count of the participants was 465.1 cells/mm(3) with an average CD4 count increase of 30.06 cells/mm(3) over 6 months from baseline CD4 count and ART initiation. Childhood age (beta = - 0.015; 95% Cl - 0.021, - 0.009), opportunistic infection at ART initiation (beta = - 0.044, 95% CI - 0.085, - 0.004), hemoglobin level (beta = 0.013; 95% CI 0.004, 0.022), and baseline WHO clinical stage II (beta = - 0.046, 95% CI - 0.091, - 0.0003) were significant predictors of CD4 changes over time. Conclusions The average CD4 count increase was sufficient in HIV patients who began combined antiretroviral therapy over time. The younger age of the infant, the higher baseline level of hemoglobin, the baseline WHO clinical stage II, and opportunistic infections led to changes in CD4 counts. As a result, timely diagnosis and treatment of opportunistic infections will reduce the risk of opportunistic infections.This publication has 30 references indexed in Scilit:
- Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in GhanaBMC Infectious Diseases, 2013
- CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHEREPLoS Medicine, 2012
- Predictors of Poor CD4 and Weight Recovery in HIV-Infected Children Initiating ART in South AfricaPLOS ONE, 2012
- Body Mass Index and CD4+ T-Lymphocyte Recovery in HIV-Infected Men with Viral Suppression on Antiretroviral TherapyHIV Research & Clinical Practice, 2011
- Absolute CD4+ T-Lymphocyte Count as a Surrogate Marker of Pediatric Human Immunodeficiency Virus Disease ProgressionThe Pediatric Infectious Disease Journal, 2008
- Long‐Term Effects of Highly Active Antiretroviral Therapy on CD4+Cell Evolution among Children and Adolescents Infected with HIV: 5 Years and CountingClinical Infectious Diseases, 2008
- Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adultsBulletin of the World Health Organization, 2008
- Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective studyAIDS, 2008
- Efficient Thymopoiesis Contributes to the Maintenance of Peripheral CD4 T Cells during Chronic Human Immunodeficiency Virus Type 2 InfectionJournal of Virology, 2007
- Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA studyHIV Medicine, 2003